×
PaxMedica EBIT 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
PaxMedica ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
PaxMedica EBIT 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
PaxMedica ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$142.2B
Bristol Myers Squibb (BMY)
$117.1B
Gilead Sciences (GILD)
$117.1B
Vertex Pharmaceuticals (VRTX)
$105.1B
CSL (CSLLY)
$85.9B
Regeneron Pharmaceuticals (REGN)
$78.5B
GSK (GSK)
$70.5B
Argenex SE (ARGX)
$38B
Alnylam Pharmaceuticals (ALNY)
$31.4B
BioNTech SE (BNTX)
$27.4B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$17.7B
Moderna (MRNA)
$15.5B
Genmab (GMAB)
$13.5B
Incyte (INCY)
$13.5B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.6B
Sarepta Therapeutics (SRPT)
$11.6B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.8B
Vaxcyte (PCVX)
$10.7B
QIAGEN (QGEN)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$9B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B